Dallos, M. C., Obradovic, A. Z., McCann, P., Chowdhury, N., Pratapa, A., Aggen, D. H., Gaffney, C., Autio, K. A., Virk, R. K., De Marzo, A. M., Antonarakis, E. S., Scher, H. I., Drake, C. G., & Rathkopf, D. E. (2024). Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer. Clinical Cancer Research, 30(22), 5218–5230. https://doi.org/10.1158/1078-0432.ccr-24-0060

Bahmad, H. F., Demus, T., Moubarak, M. M., Daher, D., Alvarez Moreno, J. C., Polit, F., Lopez, O., Merhe, A., Abou-Kheir, W., Nieder, A. M., Poppiti, R., & Omarzai, Y. (2022). Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing. Medical Sciences, 10(1), 15. https://doi.org/10.3390/medsci10010015

Kim, I. E., Jang, T. L., Kim, S., Lee, D. Y., Kim, D. D., Singer, E. A., Ghodoussipour, S., Stein, M. N., Aron, M., Dall’Era, M. A., & Yi Kim, I. (2021). Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era. Cancer Medicine, 10(22), 7909–7920. Portico. https://doi.org/10.1002/cam4.4074